Iori Okura
Chuo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine.
Journal: The Lancet. Infectious diseases
Published: August 30, 2024
Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.
Journal: The Lancet. Infectious diseases
Published: June 05, 2024
Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2.
Journal: The Lancet. Infectious diseases
Published: January 10, 2024
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Journal: The Lancet. Infectious diseases
Published: August 30, 2023
ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study.
Journal: European journal of pharmacology
Published: May 30, 2023
The differential functional coupling of phosphodiesterase 4 to human DP and EP2 prostanoid receptors stimulated with PGD2 or PGE2.
Journal: Pharmacological reports : PR
Published: October 27, 2020
Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodes.
Journal: Journal of dermatological science
Published: June 11, 2020
A novel indole compound, AWT-489, inhibits prostaglandin D2-induced CD55 expression by acting on DP prostanoid receptors as an antagonist in LS174T human colon cancer cells.
Journal: Archives of biochemistry and biophysics
Published: September 10, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026